iBio (IBIO) Interest & Investment Income (2010 - 2026)
iBio (IBIO) posted quarterly Interest & Investment Income of $657000.0 for Q1 2026, up 812.5% year-over-year from $72000.0 in Q1 2025, and up 33.27% quarter-over-quarter from $493000.0 in Q4 2025.
iBio (IBIO) Interest & Investment Income (2010 - 2026) Analysis & Trends
iBio (IBIO) has reported Interest & Investment Income for 17 consecutive years, with $657000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest & Investment Income rose 812.5% year-over-year to $657000.0; the TTM figure through Mar 2026 stood at $1.5 million (up 157.49% YoY), while the FY2025 annual figure was $437000.0, up 20.39% from the prior year.
- Interest & Investment Income grew to $657000.0 in Q1 2026 per IBIO's latest filing, from $493000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $657000.0 in Q1 2026 and bottomed at $23000.0 in Q1 2023.
- Historically, Interest & Investment Income has averaged $149176.5 across 5 years, with a median of $72000.0 in 2025.
- Annual changes were most pronounced in 2022 — Interest & Investment Income slumped 73.68% — and 2026, when it soared 812.5%.
- iBio's Interest & Investment Income stood at $41000.0 in 2022, then increased by 2.44% to $42000.0 in 2023, then surged by 166.67% to $112000.0 in 2024, then jumped by 340.18% to $493000.0 in 2025, then soared by 33.27% to $657000.0 in 2026.
- Business Quant data shows IBIO's Interest & Investment Income at $657000.0 in Q1 2026, $493000.0 in Q4 2025, and $267000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | iBio | 172.22 Mn | 172.22 Mn | - | 657,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 657,000.00 |
| Dec 31, 2025 | 493,000.00 |
| Sep 30, 2025 | 267,000.00 |
| Jun 30, 2025 | 79,000.00 |
| Mar 31, 2025 | 72,000.00 |
| Dec 31, 2024 | 112,000.00 |
| Sep 30, 2024 | 174,000.00 |
| Jun 30, 2024 | 223,000.00 |
| Mar 31, 2024 | 43,000.00 |
| Dec 31, 2023 | 42,000.00 |
| Sep 30, 2023 | 55,000.00 |
| Jun 30, 2023 | 50,000.00 |
| Mar 31, 2023 | 23,000.00 |
| Dec 31, 2022 | 41,000.00 |
| Sep 30, 2022 | 99,000.00 |
| Jun 30, 2022 | 66,000.00 |
| Mar 31, 2022 | 40,000.00 |
| Dec 31, 2021 | 35,000.00 |
| Sep 30, 2021 | 36,000.00 |
| Jun 30, 2021 | -43,000.00 |